Study: Rejuvenating Old Liver Cells May Help Prevent Alzheimer’s and Heart Disease
“We need to do further translational work to see whether our findings might point to new therapies,” Laurie DeLeve said.
Maximal clean-up potential in the liver could prevent brain and heart diseases according to a study published on November 20 in the Journal of Biological Chemistry.
- Researchers at the Keck School of Medicine of USC found that restoring aging liver cells cleared excess amyloid-beta proteins from the blood in rats.
- The experimental drug cinaciguat reopened microscopic pores in liver sinusoidal endothelial cells, improving waste filtration.
- Levels of low-density lipoprotein cholesterol and oxidized LDL also dropped significantly following the two-week treatment.
Getting drugs across the blood-brain barrier poses a 98% failure rate in clinical trials for Alzheimer’s disease. Targeting the liver first offers a more straightforward route to reduce circulating toxins.
“If we're right that the liver is impactful, what do we do about that?” first author Sam de Leve, MA, a USC lab technician and child of Laurie DeLeve, said.

Researchers focused on liver sinusoidal endothelial cells, known as LSECs, which line blood vessels and feature tiny sieve-like holes. These portals allow larger molecules to reach hepatocytes, the cells handling waste clearance. Aging causes these pores to shrink and close, leaving harmful substances in circulation.
Investigating amyloid-beta, the protein forming brain plaques in Alzheimer’s disease, the team tested the experimental drug cinaciguat on aged rats over two weeks. Cinaciguat restored cellular signaling systems and rejuvenated LSECs, reopening their pores. Treated rats showed amyloid-beta levels cut in half, dropping to match young rats, while untreated aged rats showed no change.
“We said, ‘Wait, why did that go down? Clearly, there’s more to this story,'” Sam de Leve told today.usc.edu.

Low-density lipoprotein cholesterol levels unexpectedly dropped to youthful levels during the experiment. Because LDL particles are small enough to bypass LSEC pores, researchers investigated cellular crosstalk between LSECs and hepatocytes. The drug improved chemical messaging that helps blood filtering run smoothly.
Future studies must measure amyloid-beta protein levels directly in the brain and track signs of atherosclerosis over time. “We’re hopeful, though, because the findings line up with a lot of epidemiological results showing age as a major risk factor for Alzheimer’s and atherosclerosis, and liver damage as a risk factor for Alzheimer’s,” Laurie DeLeve told ScienceAlert.